Mike Bickerdike

Mike Bickerdike

Auto-generated profile, based on publicly available information

Mike Bickerdike

Antido Therapeutics, Melbourne, Australia. 6

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
LCLyndsey S. Crump
Lyndsey S. Crump
JFJessica L. Floyd
Jessica L. Floyd
LKLi-Wei Kuo
Li-Wei Kuo
MPMiriam D. Post
Miriam D. Post
MBMike Bickerdike
Mike Bickerdike
BBBenjamin Bitler
Benjamin Bitler
High-grade serous carcinoma (HGSC) of the fallopian tube, ovary, and peritoneum is the most common type of ovarian cancer and is predicted to be immunogenic because the presence of tumor-infiltrating lymphocytes conveys a better prognosis. However, the efficacy of immunotherapies has been limited because of the immune-suppressed tumor microenvironment (TME). Tumor metabolism and immune-suppressive metabolites directly affect immune cell function through the depletion of nutrients and activation of immune-suppressive transcriptional programs. Tryptophan (TRP) catabolism is a contributor to HGSC disease progression. Two structurally distinct rate-limiting TRP catabolizing enzymes, indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2), evolved separately to catabolize TRP. IDO1/TDO2 are aberrantly expressed in carcinomas and metabolize TRP into the immune-suppressive metabolite kynurenine (KYN), which can engage the aryl hydrocarbon receptor to drive immunosuppressive transcriptional programs. To date, IDO inhibitors tested in clinical trials have had limited efficacy, but those inhibitors did not target TDO2, and we find that HGSC cell lines and clinical outcomes are more dependent on TDO2 than IDO1. To identify inflammatory HGSC cancers with poor prognosis, we stratified patient ascites samples by IL6 status, which correlates with poor prognosis. Metabolomics revealed that IL6-high patient samples had enriched KYN. TDO2 knockdown significantly inhibited HGSC growth and TRP catabolism. The orally available dual IDO1/TDO2 inhibitor, AT-0174, significantly inhibited tumor progression, reduced tumor-associated macrophages, and reduced expression of immune-suppressive proteins on immune and tumor cells. These studies demonstrate the importance of TDO2 and the therapeutic potential of AT-0174 to overcome an immune-suppressed TME. Significance: Developing strategies to improve response to chemotherapy is essential to extending disease-free intervals for patients with HGSC of the fallopian tube, ovary, and peritoneum. In this article, we demonstrate that targeting TRP catabolism, particularly with dual inhibition of TDO2 and IDO1, attenuates the immune-suppressive microenvironment and, when combined with chemotherapy, extends survival compared with chemotherapy alone.

1 October 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
LKLi-Wei Kuo
Li-Wei Kuo
LCLyndsey S. Crump
Lyndsey S. Crump
KOKathleen O'Neill
Kathleen O'Neill
MWMichelle M Williams
Michelle M Williams
Jessica L. ChristensonJessica L. Christenson
Jessica L. Christenson
JRJennifer K. Richer
Jennifer K. Richer
Anchorage-independent triple-negative breast cancer (TNBC) cells exhibit elevated levels of the tryptophan (TRP)-catabolizing enzyme tryptophan 2,3-dioxygenase 2 (TDO2) compared with the same cells grown under two-dimensional culture conditions. Tracing of 13C11-TRP demonstrated that anchorage-independent culture and/or inflammatory cytokines that activate NF-κB increase TRP catabolism and production of downstream catabolites such as kynurenine, which activate the aryl hydrocarbon receptor (AhR). TDO2 expression is heterogeneous within TNBC cell lines. To determine the function of TDO2, both pharmacologic inhibition and genetic manipulation were conducted. TDO2 knockdown revealed a compensatory increase in indoleamine 2,3-dioxygenase 1 (IDO1), a nonhomologous TRP-catabolizing enzyme, indicating that dual inhibition of these two enzymes is necessary to reliably block TRP catabolism. Thus, we tested a newly developed TDO2/IDO1 dual inhibitor, AT-0174, and found that it effectively inhibits TNBC TRP catabolism. Furthermore, AT-0174 treatment or AhR inhibitor significantly decreased TNBC anchorage-independent survival, invasive capacity, and expression of mesenchymal genes and proteins, whereas exogenous kynurenine increased invasion through AhR-mediated zinc finger E-box–binding homeobox 1 (ZEB1) expression. Thus, dual inhibition of TDO2/IDO1 may prove efficacious against TNBC progression. Significance: TDO2 is more highly expressed than the nonhomologous TRP-catabolizing enzyme IDO1 in TNBC. We find that TDO2 knockdown can lead to a compensatory increase in IDO1. Therefore, we tested a newly developed TDO2/IDO1 dual inhibitor and found that it decreases TRP catabolism, anchorage-independent survival, and invasive capacity.

3 April 2025
Verified
Other
Open access
LKLi-Wei Kuo
Li-Wei Kuo
LCLyndsey S. Crump
Lyndsey S. Crump
KOKathleen O'Neill
Kathleen O'Neill
MWMichelle M Williams
Michelle M Williams
Jessica L. ChristensonJessica L. Christenson
Jessica L. Christenson
JRJennifer K. Richer
Jennifer K. Richer
AT-0174 significantly decreased extracellular tryptophan catabolites produced by MDA-MBA-453 cells.

3 April 2025
Verified
Other
Open access
LKLi-Wei Kuo
Li-Wei Kuo
LCLyndsey S. Crump
Lyndsey S. Crump
KOKathleen O'Neill
Kathleen O'Neill
MWMichelle M Williams
Michelle M Williams
Jessica L. ChristensonJessica L. Christenson
Jessica L. Christenson
JRJennifer K. Richer
Jennifer K. Richer
Significant GSEA of Bulk RNA-seq for BT549 (under suspension condition) treated with AT-0174 vs. Vehicle

3 April 2025
Verified
Other
Open access
LKLi-Wei Kuo
Li-Wei Kuo
LCLyndsey S. Crump
Lyndsey S. Crump
KOKathleen O'Neill
Kathleen O'Neill
MWMichelle M Williams
Michelle M Williams
Jessica L. ChristensonJessica L. Christenson
Jessica L. Christenson
JRJennifer K. Richer
Jennifer K. Richer
Genetic knockdown or pharmacological inhibition of TDO2 or AhR decreased ZEB1 mRNA expression but increased while IDO1 compensated; KYN treatment increased ZEB1 expression.

16 March 2026
Verified
Other
Open access
LKLi-Wei Kuo
Li-Wei Kuo
LCLyndsey S. Crump
Lyndsey S. Crump
KOKathleen O'Neill
Kathleen O'Neill
MWMichelle M Williams
Michelle M Williams
Jessica L. ChristensonJessica L. Christenson
Jessica L. Christenson
JRJennifer K. Richer
Jennifer K. Richer
Gene enrichment set analysis (GSEA) for MDA-MB-453 forced suspension culture vs. attached culture.